Biotech and Pharmaceuticals
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
Drug pricing has emerged as a key topic to watch for pharmaceutical companies and investors in 2025. As President Donald Trump pushes for lower medicine prices for Americans, the sector is facing additional pricing pressure from a Biden-era law called the Inflation Reduction Act. The IRA, voted into law in 2022, allows the Centers for […]
Read More
Novo’s next-gen obesity drug shows positive results, heads to late-stage testing
The logo of Novo Nordisk is displayed at the 8th China International Import Expo. Sheldon Cooper | Lightrocket | Getty Images Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study. The drugmaker’s […]
Read More
Abortion pill makers brace for restrictions a year after Trump’s election
Mifepristone and Misoprostol pills are pictured Wednesday, Oct. 3, 2018, in Skokie, Illinois. Erin Hooley | Chicago Tribune | Tribune News Service | Getty Images Just over a year since Donald Trump was elected president again, the $6.9 billion abortion pill industry is operating under the same federal rules he inherited from former President Joe […]
Read More
Obesity-drugmaker Novo Nordisk helps drive Denmark’s fastest growth in years
Denmark’s economic growth accelerated in the third quarter, boosted by strong pharmaceutical exports, a key industry for the small Nordic country home to weight loss drugmaker Novo Nordisk. Denmark’s seasonally adjusted gross domestic product (GDP) grew by 2.3% in the third quarter, the largest quarter-on-quarter expansion since the fourth quarter of 2021, a preliminary reading […]
Read More
Novartis sees sales boost from key cancer drugs
FILE PHOTO: The logo of Swiss drugmaker Novartis is seen at the company’s new cell and gene therapy factory in Stein, Switzerland, November 28, 2019. Arnd Wiegmann | Reuters Swiss drugmaker Novartis on Thursday forecast sales growth of 5% to 6% per year to 2030, on a currency-adjusted basis, as higher forecast peak sales for […]
Read More
Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to […]
Read More
Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics
Exterior view of the entrance to Merck headquarters on February 05, 2024 in Rahway, New Jersey. Spencer Platt | Getty Images Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention. Merck is looking to diversify its revenue beyond Keytruda […]
Read More
Novo Nordisk’s leadership strategy tested as shareholders signal frustration ahead of vote on board revamp
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images A leadership shakeup at what was once Europe’s […]
Read More
WeightWatchers to offer Novo Nordisk’s Wegovy pill after 2026 launch
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images WeightWatchers’ CEO said on Wednesday it plans to offer Novo Nordisk’s much-anticipated Wegovy in pill form if it is launched next year in the United States, deepening its tie-up with the Danish obesity drugmaker. The […]
Read More